A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

May 31, 2031

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Interventions

DRUG

SGT-501

IV for infusion

Trial Locations (4)

University of Pennsylvania, Philadelphia

Cleveland Clinic, Cleveland

Mayo Clinic, Rochester

Boston Children's Hospital, Boston

All Listed Sponsors

lead

Solid Biosciences Inc.

INDUSTRY